Taiwan Biotech Revenue Surpasses 800 Billion, Building New National Defense Mountain

Attending a public event this week, Premier Cho Jung-tai pointed out that Taiwan's biomedical industry has demonstrated strong growth momentum over the past year, delivering impressive results in both revenue and private investment while emerging as a major engine driving Taiwan's economic transformation. According to the latest statistics from the Executive Yuan, total investment in Taiwan's biotechnology sector reached NT$55.08 billion last year, while total revenue officially surpassed the NT$805 billion mark, demonstrating the industry's exceptionally high economic multiplier effect and development potential. Faced with rapid changes in the global political and economic landscape as well as the wave of supply chain restructuring, the government's current core strategic objective is to gather valuable recommendations from industry, government, academia, and research sectors to further revise, optimize, and accelerate the formulation of policies and regulations concerning the development of biomedical technology. This effort aims to fully lead Taiwan's biotechnology industry to another historical peak, thereby creating a broader and more diverse national strategic "protective shield" following the semiconductor chip industry.

Reviewing the historical trajectory of Taiwan's industrial development, the semiconductor manufacturing industry, represented by TSMC, has long been praised by outsiders as the "sacred mountain supporting the nation" that safeguards Taiwan's economic lifeline. However, the overconcentration in a single industry has also made industry and the government realize that economic resilience requires more pillars. In recent years, global trends such as an aging population, an increase in chronic disease patients, and a comprehensive reassessment of public health safety in the wake of the COVID-19 pandemic have led to explosive growth in global demand for the biomedical and precision health industries. Taiwan possesses inherent advantages combining a top-tier medical system, outstanding clinical research talent, mature information and communications technology, and a comprehensive national health insurance database. These conditions give Taiwan an extremely high starting point in developing the biomedical industry. The Executive Yuan's particular emphasis on the high revenue and investment figures of the biotech industry is precisely intended to convey to society the government's firm determination to actively promote "industrial diversification," moving away from sole reliance on a single technology sector to make Taiwan's economic moat wider and deeper.

From a practical perspective, transforming research and development results into commercial revenue with scale requires massive capital support and a lengthy regulatory review process behind the scenes. The fact that investment in the biotech sector exceeded NT$55.08 billion last year not only signifies private capital's high confidence in the prospects of Taiwan's biotechnology, but also reflects venture capital funds, financial institutions, and major tech firms shifting their capital toward the biotech and greater health sectors. The scope of the biotechnology industry is extremely broad, ranging from new drug development, high-end medical devices, regenerative medicine, and precision medicine to digital health; every sub-sector requires a high degree of professional knowledge and regulatory cooperation. The "consolidation of recommendations from all sectors and the acceleration of policy formulation" mentioned by Cho Jung-tai actually means that the government must provide a more forward-looking and friendly regulatory environment in key areas such as intellectual property protection, relaxation of clinical trial regulations, improvement of drug review efficiency, and the integration of national health insurance coverage with commercial insurance. Only then can these massive investments truly take root and translate into substantial output value and job opportunities.

Building a broader protective shield is not merely the pursuit of breakthroughs in economic growth figures; it also carries profound significance for national security and strategic autonomy. In an era of high geopolitical tension and a background where supply chains can be disrupted at any time due to political or natural disasters, the independent supply of medical supplies, vaccine research and development, critical drugs, and high-end medical equipment has been elevated to the level of national security. If Taiwan can build strong research, development, and manufacturing capabilities in the biomedical field, it will not only be able to meet domestic health needs but also further step into the international market, playing an indispensable and critical role in the global biotech supply chain. The government expects to connect the biotech industry with surrounding precision machinery, chemical materials, artificial intelligence, and big data analysis industries through the guidance of policy tools and the integration of resources, forming a highly clustered and globally competitive innovation ecosystem—which is the true connotation of the so-called broad protective shield.

Looking ahead, although Taiwan's biomedical industry has achieved remarkable results in revenue and investment, it still faces challenges such as the difficulty of developing international markets, relatively small economies of scale, and fierce competition in talent acquisition. The focus of the government's future policy efforts will center on how to break through past policy barriers among competent authorities through cross-ministerial coordination mechanisms, establishing a one-stop guidance and support system for biotech operators. With the rapid changes in biomedical technology and the rise of AI-integrated medical diagnosis and gene therapy, Taiwan is standing at a historical crossroad of whether it can translate its existing advantages into long-term competitive momentum. The Executive Yuan's emphasis on reaching new heights and building a protective shield tests the executive team's execution and determination in regulatory innovation, capital guidance, and international networking, and this brewing industrial transformation will also determine Taiwan's critical position in the international high-tech and greater health landscape for decades to come.